Innoviva (INVA) Equity Average (2011 - 2026)
Innoviva posted quarterly Equity Average of $1.3 billion for Q1 2026, up 87.92% year-on-year from $669.0 million in Q1 2025, and up 15.2% on a QoQ basis from $1.1 billion in Q4 2025.
Innoviva (INVA) has 16 years of Equity Average data on file, last reported at $1.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 87.92% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 87.92% YoY), and the FY2025 full-year result was $1.1 billion, up 60.53% from the prior year.
- Equity Average for Q1 2026 stood at $1.3 billion, up from $1.1 billion in the prior quarter.
- Across five years, Equity Average topped out at $1.3 billion in Q1 2026 and bottomed at $539.1 million in Q1 2022.
- The 5-year median for Equity Average is $667.0 million (2024), against an average of $703.0 million.
- The widest annual swing landed in 2022, when Equity Average declined 17.35%; it then jumped 87.92% in 2026.
- A 5-year view of Equity Average shows it stood at $603.6 million in 2022, then increased by 7.89% to $651.2 million in 2023, then rose by 4.4% to $679.9 million in 2024, then soared by 60.53% to $1.1 billion in 2025, then grew by 15.2% to $1.3 billion in 2026.
- The last three Equity Average figures came in at $1.3 billion (Q1 2026), $1.1 billion (Q4 2025), and $862.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 1.26 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.26 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 862.39 Mn |
| Jun 30, 2025 | 680.86 Mn |
| Mar 31, 2025 | 669.03 Mn |
| Dec 31, 2024 | 679.85 Mn |
| Sep 30, 2024 | 667.03 Mn |
| Jun 30, 2024 | 684.60 Mn |
| Mar 31, 2024 | 689.32 Mn |
| Dec 31, 2023 | 651.22 Mn |
| Sep 30, 2023 | 591.29 Mn |
| Jun 30, 2023 | 558.29 Mn |
| Mar 31, 2023 | 563.64 Mn |
| Dec 31, 2022 | 603.58 Mn |
| Sep 30, 2022 | 603.42 Mn |
| Jun 30, 2022 | 558.84 Mn |
| Mar 31, 2022 | 539.08 Mn |
| Dec 31, 2021 | 508.87 Mn |
| Sep 30, 2021 | 442.78 Mn |
| Jun 30, 2021 | 545.21 Mn |
| Mar 31, 2021 | 652.26 Mn |
| Dec 31, 2020 | 571.35 Mn |
| Sep 30, 2020 | 513.84 Mn |
| Jun 30, 2020 | 449.34 Mn |
| Mar 31, 2020 | 373.99 Mn |
| Dec 31, 2019 | 312.94 Mn |
| Sep 30, 2019 | 265.23 Mn |
| Jun 30, 2019 | 223.32 Mn |
| Mar 31, 2019 | 179.50 Mn |
| Dec 31, 2018 | 25.39 Mn |
| Sep 30, 2018 | -131.82 Mn |
| Jun 30, 2018 | -184.06 Mn |
| Mar 31, 2018 | -227.73 Mn |
| Dec 31, 2017 | -232.83 Mn |
| Sep 30, 2017 | -259.85 Mn |
| Jun 30, 2017 | -315.46 Mn |
| Mar 31, 2017 | -343.59 Mn |
| Dec 31, 2016 | -360.43 Mn |
| Sep 30, 2016 | -365.48 Mn |
| Jun 30, 2016 | -362.54 Mn |
| Mar 31, 2016 | -352.31 Mn |
| Dec 31, 2015 | -332.82 Mn |
| Sep 30, 2015 | -308.50 Mn |
| Jun 30, 2015 | -277.07 Mn |
| Mar 31, 2015 | -241.75 Mn |
| Dec 31, 2014 | -208.24 Mn |
| Sep 30, 2014 | -190.33 Mn |
| Jun 30, 2014 | 37.86 Mn |
| Mar 31, 2014 | 281.19 Mn |
| Dec 31, 2013 | 314.59 Mn |
| Sep 30, 2013 | 207.85 Mn |
| Jun 30, 2013 | 88.58 Mn |
| Mar 31, 2013 | 123.27 Mn |
| Dec 31, 2012 | 164.16 Mn |
| Sep 30, 2012 | 181.27 Mn |
| Jun 30, 2012 | 97.69 Mn |
| Mar 31, 2012 | -40.46 Mn |
| Dec 31, 2011 | -73.10 Mn |
| Sep 30, 2011 | -48.32 Mn |